Multiple Myeloma (MM) Recruiting Phase 2 Trials for Thiotepa (DB04572)

Also known as: MULTIPLE MYELOMA (MM) / Multiple myeloma / Myeloma, Multiple / Multiple Myelomas / Multiple Myeloma(MM) / Plasma cell myelomas / Myelomatosis multiple / Peripheral plasma cell myeloma / Myelomatosis / Multiple myeloma myelomatosis / Plasma cell myeloma / Myeloma / Multiple myeloma with failed remission

IndicationStatusPhase
DBCOND0040908 (Multiple Myeloma (MM))Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01119066HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic MalignanciesTreatment
NCT01746849Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell TransplantationTreatment
NCT02861417Timed Sequential Busulfan and Post Transplant Cyclophosphamide for Allogeneic TransplantationTreatment
NCT02507479Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid MalignanciesTreatment